My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 354

    1.

    Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

    Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.

    Diabetes Care. 2007 Oct;30(10):2447-52. Epub 2007 Jul 10. Erratum in: Diabetes Care. 2008 Jan;31(1):188. PMID: 17623819 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

    Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E.

    Diabetes. 2004 Jun;53(6):1614-20.PMID: 15161770 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

    Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR.

    Diabetes Care. 2005 May;28(5):1107-12.PMID: 15855574 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.

    King AB.

    Diabetes Obes Metab. 2009 Jan;11(1):69-71.PMID: 19120433 [PubMed - indexed for MEDLINE]Related articles

    5.

    Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.

    Diabetes Obes Metab. 2007 May;9(3):290-9.PMID: 17391154 [PubMed - indexed for MEDLINE]Related articles

    6.

    Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

    Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB.

    Diabetes. 2000 Dec;49(12):2142-8.PMID: 11118018 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.

    Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR.

    Exp Clin Endocrinol Diabetes. 2007 Jul;115(7):461-7.PMID: 17647145 [PubMed - indexed for MEDLINE]Related articles

    8.

    Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study: response to Porcellati et al.

    Banarer S.

    Diabetes Care. 2008 Mar;31(3):e16; author reply e17. No abstract available. PMID: 18308679 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.

    Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.

    Diabet Med. 2006 Mar;23(3):285-92.PMID: 16492212 [PubMed - indexed for MEDLINE]Related articles

    10.

    Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.

    Ashwell SG, Gebbie J, Home PD.

    Diabet Med. 2006 Aug;23(8):879-86.PMID: 16911626 [PubMed - indexed for MEDLINE]Related articles

    11.

    Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.

    Kabadi UM.

    Clin Drug Investig. 2008;28(11):697-701.PMID: 18840012 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.

    Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI.

    Diabet Med. 2007 Jun;24(6):635-42. Epub 2007 Mar 22.PMID: 17381500 [PubMed - indexed for MEDLINE]Related articles

    13.

    A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.

    Diabetologia. 2008 Mar;51(3):408-16. Epub 2008 Jan 16.PMID: 18204830 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.

    Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.

    Diabet Med. 2006 May;23(5):522-8.PMID: 16681561 [PubMed - indexed for MEDLINE]Related articles

    15.

    Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?

    Valensi P, Cosson E.

    Diabetes Metab. 2005 Sep;31(4 Pt 2):4S34-4S39. Review.PMID: 16389896 [PubMed - indexed for MEDLINE]Related articles

    16.

    Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.

    Roach P, Malone JK.

    Diabet Med. 2006 Jul;23(7):743-9.PMID: 16842478 [PubMed - indexed for MEDLINE]Related articles

    17.

    The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

    Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.

    Diabetes Technol Ther. 2008 Dec;10(6):479-85.PMID: 19049377 [PubMed - indexed for MEDLINE]Related articles

    18.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    19.

    Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.

    Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T.

    Clin Ther. 2007 May;29(5):927-34.PMID: 17697911 [PubMed - indexed for MEDLINE]Related articles

    20.

    Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.

    Luzio SD, Beck P, Owens DR.

    Horm Metab Res. 2003 Jul;35(7):434-8.PMID: 12931275 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity